Search Results - "Kamiyama, Emi"

Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs by Rozehnal, Veronika, Nakai, Daisuke, Hoepner, Ursula, Fischer, Thomas, Kamiyama, Emi, Takahashi, Masayuki, Yasuda, Satoru, Mueller, Juergen

“…The purpose of this study was to validate human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for predicting the oral drug…”
Get full text

Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males by Kato, Manabu, Furuie, Hidetoshi, Kamiyama, Emi, Shiosakai, Kazuhito, Yoshihara, Kazutaka, Taguchi, Takashi

“…Background and objectives G protein-coupled receptor 119 (GPR119) agonists reduce plasma glucose by promoting insulin secretion in a glucose-dependent manner…”
Get full text

Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor by YAMADA, Akihiro, MAEDA, Kazuya, ADACHI, Yasuhisa, ZHUOHAN HU, KUSUHARA, Hiroyuki, SUGIYAMA, Yuichi, KAMIYAMA, Emi, SUGIYAMA, Daisuke, KONDO, Tsunenori, SHIROYANAGI, Yoshiyuki, NAKAZAWA, Hayakazu, OKANO, Teruo, ADACHI, Masashi, SCHUETZ, John D

“…Olmesartan, a novel angiotensin II AT1-receptor antagonist, is excreted into both bile and urine, with minimal metabolism. Because olmesartan is a hydrophilic…”
Get full text

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors by Shitara, Kohei, Satoh, Taroh, Iwasa, Satoru, Yamaguchi, Kensei, Muro, Kei, Komatsu, Yoshito, Nishina, Tomohiro, Esaki, Taito, Hasegawa, Jun, Kakurai, Yasuyuki, Kamiyama, Emi, Nakata, Tomoko, Nakamura, Kota, Sakaki, Hayato, Hyodo, Ichinosuke

“…Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a…”
Get full text

Culture Period-Dependent Change of Function and Expression of ATP-Binding Cassette Transporters in Caco-2 Cells by KAMIYAMA, Emi, SUGIYAMA, Daisuke, NAKAI, Daisuke, MIURA, Shin-Ichi, OKAZAKI, Osamu

“…The objective of this study was to determine an appropriate culture period to assess whether a compound of interest is transported by efflux transporters such…”
Get full text

Metabolism and disposition of [14C]tivantinib after oral administration to humans, dogs and rats by Murai, Takahiro, Takakusa, Hideo, Nakai, Daisuke, Kamiyama, Emi, Taira, Tomoe, Kimura, Tomoko, Jimbo, Takeshi, Bathala, Mohinder, Pickersgill, Fraser, Zahir, Hamim, Tokui, Taro, Savage, Ronald E., Ashwell, Mark A., Izumi, Takashi

“…Abstract 1. The biotransformation and disposition of tivantinib in humans, dogs and rats was examined after a single oral administration of [14C]tivantinib…”
Get full text

Inhibitory Effects of Angiotensin Receptor Blockers on CYP2C9 Activity in Human Liver Microsomes by Kamiyama, Emi, Yoshigae, Yasushi, Kasuya, Atsushi, Takei, Makoto, Kurihara, Atsushi, Ikeda, Toshihiko

“…We investigated the inhibitory effects of the angiotensin receptor blockers (ARBs), candesartan, irbesartan, losartan, losartan active metabolite (EXP-3174),…”
Get full text

Characterization of CS-023 (RO4908463), a Novel Parenteral Carbapenem Antibiotic, and Meropenem as Substrates of Human Renal Transporters by Shibayama, Takahiro, Sugiyama, Daisuke, Kamiyama, Emi, Tokui, Taro, Hirota, Takashi, Ikeda, Toshihiko

“…To characterize the renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem in humans, we examined their affinities as…”
Get full text

Synthesis and evaluation of CS-2100, a potent, orally active and S1P3- sparing S1P1 agonist by Nakamura, Tsuyoshi, Asano, Masayoshi, Sekiguchi, Yukiko, Mizuno, Yumiko, Tamaki, Kazuhiko, Nara, Futoshi, Kawase, Yumi, Yabe, Yoshiyuki, Nakai, Daisuke, Kamiyama, Emi, Urasaki-Kaneno, Yoko, Shimozato, Takaichi, Doi-Komuro, Hiromi, Kagari, Takashi, Tomisato, Wataru, Inoue, Ryotaku, Nagasaki, Miyuki, Yuita, Hiroshi, Oguchi-Oshima, Keiko, Kaneko, Reina, Nishi, Takahide

“…Modulators of sphingosine phosphate receptor-1 (S1P1) have recently been focused as a suppressant of autoimmunity. We have discovered a 4-ethylthiophene-based…”
Get full text

Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure-Response Analysis by Yoshihara, Kazutaka, Kobayashi, Yoshimasa, Endo, Seiko, Fukae, Masato, Hennig, Stefanie, Kastrissios, Helen, Kamiyama, Emi, Garimella, Tushar, Abutarif, Malaz

“…This study evaluated the benefit/risk of trastuzumab deruxtecan (T-DXd) 6.4 mg/kg in patients with human epidermal growth factor receptor 2 (HER2)-positive…”
Get full text

Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer by Shimomura, Akihiko, Takano, Toshimi, Takahashi, Shunji, Sagara, Yasuaki, Watanabe, Junichiro, Tokunaga, Eriko, Shinkai, Tetsu, Kamio, Takahiro, Kikumori, Kunika, Kamiyama, Emi, Fujisaki, Yoshihiko, Saotome, Dan, Yamashita, Toshinari

“…HER2‐targeted anticancer therapies may be associated with cardiovascular adverse events. This study evaluated effects of the HER2‐targeted antibody–drug…”
Get full text

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors by Takahashi, Shunji, Karayama, Masato, Takahashi, Masato, Watanabe, Junichiro, Minami, Hironobu, Yamamoto, Noboru, Kinoshita, Ichiro, Lin, Chia-Chi, Im, Young-Hyuck, Achiwa, Issei, Kamiyama, Emi, Okuda, Yasuyuki, Lee, Caleb, Bang, Yung-Jue

“…To evaluate drug-drug interactions between the human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd;…”
Get full text

Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer by Shimizu, Toshio, Yonesaka, Kimio, Hayashi, Hidetoshi, Iwasa, Tsutomu, Haratani, Koji, Yamada, Hironori, Ohwada, Shoichi, Kamiyama, Emi, Nakagawa, Kazuhiko

“…Background This phase 1 study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287) Process 2, a new formulation of fully…”
Get full text

Abstract P1-18-12: A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer by Yamashita, Toshinari, Shimomura, Akihiko, Takano, Toshimi, Sagara, Yasuaki, Watanabe, Junichiro, Tokunaga, Eriko, Kikumori, Kunika, Kamiyama, Emi, Kamio, Takahiro, Nakamura, Ryo, Shinkai, Tetsu, Takahashi, Shunji

“…Background [Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a) is a novel antibody-drug conjugate with a humanized anti-HER2 antibody, peptide-based…”
Get full text

Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors by Satoh, Taroh, Shitara, Kohei, Iwasa, Satoru, Yamaguchi, Kensei, Muro, Kei, Komatsu, Yoshito, Nishina, Tomohiro, Esaki, Taito, Hasegawa, Jun, Kakurai, Yasuyuki, Kamiyama, Emi, Nakata, Tomoko, Nakamura, Kota, Hyodo, Ichinosuke

“…Abstract only 99 Background: Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface of many tumors and is associated…”
Get full text

Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes by Kamiyama, Emi, Nakai, Daisuke, Mikkaichi, Tsuyoshi, Okudaira, Noriko, Okazaki, Osamu

“…The inhibitory effect of angiotensin II type 1 receptor blockers (ARBs) on P-glycoprotein (P-gp) was examined to evaluate their clinical drug–drug interaction…”
Get full text

Pharmacological and clinical study results of trastuzumab deruxtecan (T-DXd, ENHERTU ® ) by Saito, Kaku, Kaneko, Reina, Kamio, Takahiro, Kamiyama, Emi, Muto, Ryo, Sugihara, Masahiro

“…Antibody-drug conjugates (ADCs) combine the specific antibody and cytotoxic agent by a linker and represent a promising drug class with a wider therapeutic…”
Get more information

Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer by Chang, Dwan-Ying, Lin, Chia-Chi, Chen, Tom Wei-Wu, Lin, Ching-Hung, Lee, Jih-Hsiang, Chao, Ta-Chung, Liu, Chun-Yu, Achiwa, Issei, Kamiyama, Emi, Okuda, Yasuyuki, Lee, Caleb, Chao, Yee

“…Background: Anti-HER2 therapies are beneficial for patients with HER2+ gastric or breast cancer (BC). [Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a)…”
Get full text

Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study by Kato, Manabu, Ishizuka, Hitoshi, Taguchi, Takashi, Shiosakai, Kazuhito, Kamiyama, Emi, Sata, Michio, Yoshida, Takafumi

“…Introduction The pharmacokinetics, safety, and tolerability of DS-8500a (a G protein receptor 119 agonist) up to 100 mg have been investigated in healthy…”
Get full text

Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects by Maekawa, Yutaro, Furuie, Hidetoshi, Kato, Manabu, Myobatake, Yusuke, Kamiyama, Emi, Watanabe, Akiko, Shiosakai, Kazuhito, Taguchi, Takashi, Bass, Robert, Zhou, Jin, Dishy, Victor, Warren, Vance, Vashi, Vijay, Ishizuka, Hitoshi

“…Background Non-clinical study data suggest that DS-8500a, a G protein-coupled receptor 119 agonist, exhibits antidiabetic activity, inhibition of some…”
Get full text